Minor
TIGOS-LS · BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
Enrollment closed, study ongoing
SCRI Development Innovations, LLCPhase 2 NCT06773910 Registry history of NCT06773910 on ClinicalTrials.gov (opens the registry)